Patent application number | Description | Published |
20090252683 | Composition Comprising Cross-Species-Sepecific Antibodies and uses Thereof - The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific anti-bodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases. | 10-08-2009 |
20100150918 | CROSS-SPECIES-SPECIFIC BINDING DOMAIN - The present invention relates to a polypeptide comprising a human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. In a further aspect the invention provides a method for the identification of polypeptides comprising a cross-species specific binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ε (CD3 epsilon). | 06-17-2010 |
20100183615 | CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS - The present invention relates to a polypeptide comprising a first human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. | 07-22-2010 |
20120121600 | PHARMACEUTICAL ANTIBODY COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA - The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” or (ii) a CDR-H1 having the amino acid sequence “TYAMH” and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” and a CDR-H3 having the amino acid sequence “DRGLRFYFDY”. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed. | 05-17-2012 |
20120244162 | CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS - The present invention relates to a polypeptide comprising a first human binding domain capbable of binding to an epitope of human and non-chimpanzee CD3ε (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acid sequences encoding the polypeptide, to vectors comprising the nucleic acid sequences and to host cells comprising the nucleic acid sequences or vectors containing the nucleic acid sequences. In another aspect, the invention provides for a pharmaceutical composition comprising the polypeptide and methods of medical treatment or use of the polypeptide. | 09-27-2012 |
20130129729 | COMPOSITIONS COMPRISING CROSS-SPECIES-SPECIFIC ANTIBODIES AND USES THEREOF - The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific antibodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases. | 05-23-2013 |
20130273050 | PHARMACEUTICAL COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA - The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, where the second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7, a pharmaceutical composition comprising the bispecific single chain antibody, and methods for the treatment of an epithelial tumor in a human with the pharmaceutical compositions containing the bispecific single chain antibody. Furthermore, processes for the production of the pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed. | 10-17-2013 |
Patent application number | Description | Published |
20110293619 | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY - The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain anti-body molecule. | 12-01-2011 |
20120034228 | CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY - The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an antigen selected from the group consisting of Prostate Stem Cell Antigen (PSCA), B-Lymphocyte antigen CD19 (CD19), hepatocyte growth factor receptor (C-MET), Endosialin, the EGF-like domain 1 of EpCAM, encoded by exon 2, Fibroblast activation protein alpha (FAP alpha) and Insulin-like growth factor I receptor (IGF-IR or IGF-1R). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule. | 02-09-2012 |
20130129730 | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY - The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule. | 05-23-2013 |
20130156769 | BINDING MOLECULES FOR BCMA AND CD3 - The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule. | 06-20-2013 |
20130156770 | BINDING MOLECULES FOR BCMA AND CD3 - The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule. | 06-20-2013 |
20140322218 | Antibody Constructs for CDH19 and CD3 - The present invention provides to a antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention relates to a nucleic acid sequence encoding the antibody construct, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention relates a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct. | 10-30-2014 |
20140348837 | BINDING MOLECULES FOR BCMA AND CD3 - The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule. | 11-27-2014 |
20150023967 | BINDING MOLECULES FOR BCMA AND CD3 - The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster3 of BCMA, and the second binding domain is capable of binding to the Tcell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule. | 01-22-2015 |
Patent application number | Description | Published |
20090049678 | METHOD AND APPARATUS FOR PRODUCING A WINDING FOR ELECTRICAL MACHINES - The invention relates to an electrical machine having a stator winding, its manufacturing method and manufacturing apparatus, wherein the winding is manufactured with a predetermined number of coils on automated winding machines and is then embossed in the region of the longitudinal sides of the coils such that the longitudinal sides ( | 02-26-2009 |
20090145995 | WINDING DEVICE FOR A FIELD COIL, PROCESSING EQUIPMENT AND ELECTRIC MACHINE - The invention relates to a winding device for producing a field coil ( | 06-11-2009 |
20100283349 | POLYPHASE ELECTRICAL MACHINE - A polyphase electrical machine, in particular, a polyphase generator, includes a stator which features a core body having a circumferential slot pitch, and a winding configuration having a plurality of windings. It is provided that each winding and each slot of the group of slots that extends over one pole pitch is assigned to one of the phases, and the windings have winding sections that lie in assigned slots and between which, in each case, a winding-head connection is formed, the winding-head connections of different windings being disposed radially in layers relative to each other, and the number of phases being five. A method for producing a polyphase electrical machine is also provided. | 11-11-2010 |
20100295390 | STATOR FOR A POLYPHASE ELECTRIC MACHINE AND METHOD FOR MANUFACTURING SAME | 11-25-2010 |
20110043059 | ALTERNATING CURRENT GENERATOR COMPRISING A STATOR AND A STATOR WINDING INSERTED IN STATOR GROOVES MADE OF WINDING ELEMENTS AND METHOD FOR PRODUCING AN INVENTIVE STATOR - An alternating-current generator, in particular a three-phase generator, for a motor vehicle, having a rotor including north and south poles, particularly having claw-pole fingers extending in the axial direction and alternating as north and south poles at the rotor's periphery, a stator having a magnetic core, especially laminated core, having slots and a stator winding disposed in the magnetic core's slots, the stator winding having winding overhangs that are coolable by an approximately radial air flow produced by at least one fan mounted at the rotor, the stator being situated opposite the rotor, and the stator and the rotor having defined positions relative to each other, the multiphase stator winding being made up of winding elements, at least one winding element having more than two sections inserted in slots, and at least one winding element having more than one reversal section which brings about a change in the radial position. | 02-24-2011 |
20120139383 | METHOD FOR PRODUCING A STATOR WINDING OF AN ELECTRIC MACHINE, IN PARTICULAR FOR PRODUCING AN ALTERNATOR - The invention relates to a method for producing a stator winding ( | 06-07-2012 |
20130328435 | METHOD FOR PRODUCING A STATOR WINDING OF AN ELECTRIC MACHINE, IN PARTICULAR FOR PRODUCING AN AC GENERATOR - Method for producing a stator winding ( | 12-12-2013 |
20140035427 | METHOD FOR PRODUCING A STATOR WINDING OF AN ELECTRIC MACHINE, IN PARTICULAR AN AC GENERATOR - Method for producing a stator winding ( | 02-06-2014 |
Patent application number | Description | Published |
20080241102 | Polymeric Prodrug with a Self-Immolative Linker - A cascade carrier linked prodrug is described which comprises a biologically active moiety and a masking group having at least one nucleophile and being distinct from the carrier. | 10-02-2008 |
20100291021 | ALIPHATIC PRODRUG LINKER - A polymeric prodrug is described which comprises at least one polymer attached via at least one permanent bond to a bicine linker. The bicine linker is attached via a temporary linkage to an amine containing biologically active moiety. The amine containing biologically active moiety—such as a drug—can be released by cleaving the temporary linkage. | 11-18-2010 |
20110009315 | LONG-ACTING TRANSIENT POLYMER CONJUGATES OF EXENDIN - Long-acting polymer exendin-4 or exendin agonist derivatives of the formula Pol-L-E are provided wherein Pol is a polymer, L is a releasing linker undergoing slow autohydrolysis and E is an exendin or exendin agonist. These exendin or exendin agonists are slowly released from Pol-L upon administration to a living organism. The derivatives are useful e.g. for the treatment of diabetes mellitus. | 01-13-2011 |
20110053848 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L | 03-03-2011 |
20110112021 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS - A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial. | 05-12-2011 |
20110172390 | Protein-Proteophore Complexes - The application relates to a composition comprising a hyperbranched polymer attached to a core and a biologically active moiety. The biologically active moiety is attached to the core by means of a substantially non-enzymatically cleavable linker L. The composition can be used to deliver the biologically active moiety to its target. | 07-14-2011 |
20110223230 | HYDROGEL FORMULATIONS - A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety. | 09-15-2011 |
20120058084 | Interferon Alpha Carrier Prodrugs - The present invention relates to a pharmaceutical composition comprising a water-soluble polymeric carrier linked prodrug of interferon alpha, wherein the prodrug is capable of releasing free interferon alpha, wherein the release half life under physiological conditions is at least 4 days. The invention further relates to prodrugs for said pharmaceutical composition and their use for treating, controlling, delaying or preventing a condition that can benefit from interferon alpha treatment, such as hepatitis C. | 03-08-2012 |
20120183616 | LONG ACTING INSULIN COMPOSITION - The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition. | 07-19-2012 |
20120184489 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an insulin linker conjugate D-L, wherein D represents the insulin moiety; and -L is a non-biologically active linker moiety -L | 07-19-2012 |
20130150281 | POLYMERIC PRODRUG WITH SELF-IMMOLATIVE LINKER - A cascade carrier linked prodrug is described comprising a biologically active moiety and a masking group having at least one nucleophile and being distinct from the carrier. | 06-13-2013 |
20130189328 | PRODRUGS COMPRISING AN EXENDIN LINKER CONJUGATE - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an exendin linker conjugate D-L, wherein D represents an exendin moiety; and -L is a non-biologically active linker moiety -L | 07-25-2013 |
20150057221 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L | 02-26-2015 |
20150196667 | STERILIZATION OF BIODEGRADABLE HYDROGELS - The present invention relates to a terminal sterilization process for biodegradable PEG-based insoluble hydrogels using irradiation. The presence of a protective solvent ensures that the hydrogel remains intact with functionally preserved three-dimensional and physicochemical properties. | 07-16-2015 |
20150202317 | DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a drug linker conjugate D-L, wherein D being a biologically active moiety containing an aliphatic amine group is conjugated to one or more polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeutically useful half-lives. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments. | 07-23-2015 |
20150238625 | HYDROGEL FORMULATIONS - A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety. | 08-27-2015 |
Patent application number | Description | Published |
20120156259 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels - The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament. | 06-21-2012 |
20120156260 | Prodrugs Containing an Aromatic Amine Connected By an Amido Bond to a Linker - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein an aromatic amine containing biologically active moiety is connected (bound) by an amido bound to a linker. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments. | 06-21-2012 |
20120191039 | CARRIER LINKED PRAMIPEXOLE PRODRUGS - The present invention relates to a carrier linked pramipexole prodrug or a pharmaceutical acceptable salt thereof, wherein pramipexole is bound via a linker to a polymeric carrier. The invention also relates to pharmaceutical compositions comprising said polymeric pramipexole prodrug and their use as medicaments. | 07-26-2012 |
20120253071 | Sterilization of biodegradable hydrogels - The present invention relates to a terminal sterilization process for biodegradable PEG-based insoluble hydrogels using irradiation. The presence of a protective solvent ensures that the hydrogel remains intact with functionally preserved three-dimensional and physicochemical properties. | 10-04-2012 |
20120277253 | SUBCUTANEOUS PALIPERIDONE COMPOSITION - The present invention relates to pharmaceutical composition for subcutaneous injection comprising a paliperidone compound wherein the composition releases the paliperidone with an immediate onset of action and continuously for at least 3 weeks, and wherein the composition has a pharmacokinetic profile in vivo with substantially no burst release of the paliperidone. The compositions are useful as medicaments for the treatment of psychotic disorders and diseases. | 11-01-2012 |
20120322721 | DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER - The present invention relates to dry compositions of rhGH polymer prodrug containing a lyoprotectant and, optionally, one or more than one excipient. Such compositions are stable for at least 1 year, when stored at 2-8° C. The invention further relates to methods of manufacturing said compositions, containers comprising such composition as well as a kit of parts. | 12-20-2012 |
20130030359 | DIPEPTIDE-BASED PRODRUG LINKERS FOR AROMATIC AMINE-CONTAINING DRUGS - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a drug linker conjugate D-L, wherein D being a biologically active moiety containing an aromatic amine group is conjugated to one or more polymeric carriers via dipeptide-containing linkers. Such carrier-linked prodrugs achieve drug releases with therapeutically useful half-lives. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments. | 01-31-2013 |
20130035635 | CARRIER-LINKED CARBAMATE PRODRUG LINKERS - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a drug linker conjugate D-L, wherein D being a biologically active moiety containing an aromatic hydroxyl group is conjugated to one or more polymeric carriers via secondary carbamate-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeutically useful half-lives. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments. | 02-07-2013 |
20130053405 | CARRIER LINKED PALIPERIDONE PRODRUGS - The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent Paliperidone carrier conjugate of formula (I) | 02-28-2013 |
20140249093 | Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages - The invention provides a carrier-linked prodrugs, wherein the biologically active moieties comprise at least one carboxylic acid and wherein the linkage between the drug moiety and linker is in the form of an ester wherein the hydroxyl group required for ester formation is provided by the linker moiety and the carboxyl group required for ester formation is provided by the drug moiety. The hydroxyl group of the linker is sterically hindered by the presence of an alkyl or aryl group on the carbon directly bound to or adjacent to the carbon carrying the hydroxyl group (α-carbon). The steric effect of the alkyl or aryl group enables greater control of the rate of hydrolytic degradation of such carrier-linked prodrugs. | 09-04-2014 |
20140296150 | Carrier-Linked Treprostinil Prodrugs - The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH). | 10-02-2014 |
20140296257 | High-Loading Water-Soluable Carrier-Linked Prodrugs - The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein B, A and Hyp form the carrier, B is a branching core, each A is independently a poly(ethylene glycol)-based polymeric chain, each Hyp is independently a branched moiety, each SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, each D is independently a biologically active moiety, each x is independently 0 or 1, each m is independently an integer of from 2 to 64, n is an integer from 3 to 32; or the pharmaceutically acceptable salt thereof. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs, their use as medicament or diagnostic, and methods of treatment. | 10-02-2014 |
20140303245 | Sustained Release Composition of Prostacyclin - The present invention relates to sustained release compositions of prostacyclin, as well as uses thereof, in particular for the prevention and/or treatment of pulmonary arterial hypertension. | 10-09-2014 |
20150087688 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a biologically active moiety-linker conjugate D-L, wherein D is a hydroxyl-comprising biologically active moiety; and L is a promoiety comprising a moiety L | 03-26-2015 |
Patent application number | Description | Published |
20100025619 | Method for heating and cooling using fluoroether compounds, compositions suitable therefore and their use - Compounds of general formula (I) C | 02-04-2010 |
20100029531 | Nonflammable compositions comprising fluorinated compounds and use of these compositions - The invention relates to non-flammable compositions comprising fluorinated compounds selected from the group consisting of hydrofluoroalkanes, hydrofluoroalkenes, partially or perfluorinated aromatic compounds, hydrofluoroethers or fluoroketones, 1,2-dichloroethylene, especially trans-1,2-dichloroethylene, and a stabilizer. These non-flammable compositions which preferably contain 1,1,1,3,3-pentafluorobutane, can be used especially as solvents for cleaning and defluxing electronic components and for degreasing metals. The compositions further may comprise a propellant, e.g. 1,1,1,2-tetrafluoroethane. These compositions are especially suitable as flushing agent. | 02-04-2010 |
20100314574 | Refrigerant composition - A composition which comprises or consists of more than 75 to less than 80 wt. % of pentafluoroethane (HFC-125); more than 17 to less than 22.7 wt. % of 1,1,1,2-tetrafluoroethane (HFC-134a); and more than 2.3 to less than 3.0 wt. % of n-butane (R600). | 12-16-2010 |
20130079267 | Nonflammable compositions comprising fluorinated compounds and use of these compositions - Nonflammable compositions comprising fluorinated compounds selected from the group consisting of hydrofluoroalkanes, hydrofluoroalkenes, partially or perfluorinated aromatic compounds, hydrofluoroethers, and fluoroketones; 1,2-dichloroethylene, especially trans-1,2-dichloroethylene; and a stabilizer. These non-flammable compositions which preferably contain 1,1,1,3,3-pentafluorobutane, can be used especially as solvents for cleaning and defluxing electronic components and for degreasing metals. The compositions further may comprise a propellant, e.g. 1,1,1,2-tetrafluoroethane. These compositions are especially suitable as flushing agent. | 03-28-2013 |
20140319407 | NOVEL USE FOR COMPOSITIONS COMPRISING HFC-134A AND HFO-1234YF AND AN AZEOTROPIC COMPOSITION THEREOF - Hydrofluorocarbon compositions which consist of more than 50 to less than 60% wt of HFO-1234yf, and of more than (40) to less than 50 wt % HFC-134a are useful as drop-in substitutes for R-404A, R-507 and R-22. The invention also concerns azeotropic hydrofluorocarbon compositions consisting equal to or more than 56.3 to equal to or less than 58.0 wt of HFO-1234yf, and equal to or more than 42.0 to equal to or less than 43.7% wt of HFC-134a. | 10-30-2014 |
Patent application number | Description | Published |
20080218721 | OPTICAL ELEMENT UNIT - An optical element unit including an optical element and an optical element holder is disclosed. The optical element holder includes a holding element and coupling elements. The holding element holds the optical element and is made of a ceramic material. The elastic coupling elements are attached to the holding element and contact the optical element. The elastic coupling elements provide deformation decoupling between the holding element and the optical element. | 09-11-2008 |
20080278828 | Optical Element - An optical element has at least one additional element fitted thereon which dissipates the vibrational energy of the optical element by friction. | 11-13-2008 |
20090174874 | Optical Projection System - An optical projection unit comprising a first optical element module and at least one second optical element module is provided. The first optical element module comprises a first housing unit and at least a first optical element, the first optical element being received within the first housing unit and having an optically used first region defining a first optical axis. The at least one second optical element module is located adjacent to the first optical element module and comprises at least one second optical element, the second optical element defining a second optical axis of the optical projection unit. The first housing unit has a central first housing axis and an outer wall extending in a circumferential direction about the first housing axis. The first optical axis is at least one of laterally offset and inclined with respect to the first housing axis. Furthermore, the first housing axis is substantially collinear with the second optical axis. | 07-09-2009 |
20090244508 | METHOD AND DEVICE FOR CONNECTING AN OPTICAL ELEMENT TO A FRAME - A method and a device for the material-fit connection of an optical element to a frame are disclosed. | 10-01-2009 |
20120194795 | OPTICAL ELEMENT - An optical element has at least one additional element fitted thereon which dissipates the vibrational energy of the optical element by friction. | 08-02-2012 |
20130044304 | OPTICAL PROJECTION SYSTEM - An optical projection unit comprising a first optical element module and at least one second optical element module is provided. The first optical element module comprises a first housing unit and at least a first optical element, the first optical element being received within the first housing unit and having an optically used first region defining a first optical axis. The at least one second optical element module is located adjacent to the first optical element module and comprises at least one second optical element, the second optical element defining a second optical axis of the optical projection unit. The first housing unit has a central first housing axis and an outer wall extending in a circumferential direction about the first housing axis. The first optical axis is at least one of laterally offset and inclined with respect to the first housing axis. Furthermore, the first housing axis is substantially collinear with the second optical axis. | 02-21-2013 |
Patent application number | Description | Published |
20080275607 | Method for Operating an Active Chassis System - A method is provided for operating an active chassis system, in which wheels of at least one axle are arranged with a toe-in angle, and actuating elements which interact with supporting assemblies which are arranged between the wheels and a vehicle body. Wheel contact forces of the wheels assume different values as a result of the actuating elements being actuated. A side force is generated at the wheels which have a toe-in angle, and a resulting yaw moment is produced. A desired yaw rate is determined based upon information from a device which is arranged in the vehicle in order to determine the profile of the roadway in a control unit, and the wheel contact forces are set as a function of the desired yaw rate. | 11-06-2008 |
20100262328 | Method and Apparatus for Influencing the Transverse Dynamics of a Vehicle - In a method and apparatus for influencing transverse dynamics of a vehicle, for a chassis intervention is carried out when an intervention condition is met. The intervention condition is met when the value of a determined transverse dynamics disturbance variable is higher than a disturbance variable threshold value, and when one or a group of the following criteria is met:
| 10-14-2010 |
20110112722 | Method for influencing the transverse dynamics of a vehicle - The present invention relates to a method for influencing the transversal dynamics of a vehicle ( | 05-12-2011 |
20140200766 | Method for Operating a Side Wind Assistant for a Vehicle and Side Wind Assistant for a Vehicle - A side wind assistant for a vehicle and a method for the operation of the side wind assistant involve detecting a side wind disturbance acting on the vehicle and reacting to the side wind disturbance by carrying out a side wind compensation intervention to at least partially compensate for the influence of the side wind disturbance, at least when an intervention threshold has been exceeded. The side wind assistant thus reacts to the side wind disturbance in a frequency selective manner in which the frequency selectivity is controlled depending on the side wind compensation or a state of the side wind assistant correlating with the side wind compensation intervention. In particular, the frequency selectivity is controlled depending on whether the side wind compensation intervention is carried out or not carried out, and depending on the duration of the side wind compensation intervention. | 07-17-2014 |
Patent application number | Description | Published |
20090191297 | TABLET PRESS - A tablet press with a rotor, which is rotatably mounted in a stand of the tablet press and which has an upper punch accommodation for the upper punches and a lower punch accommodation for the lower punches of the tablet press, as well as a die plate with a series of die bores which are aligned with the upper and the lower punches, wherein the die plate consists of at least two ring segments which can be attached on the rotor by means of a fastening device, wherein clamping elements are arranged in axis parallel passages of the rotor spaced apart in the perimeter distance, which act against the ring segments from the bottom side and clamp against an abutment surface of the rotor, characterised in that at least one drive device for the clamping elements is arranged in the stand of the tablet press, with a coupling element adjustable in the height, which can be selectively set into engagement with the lower end of the clamping element. | 07-30-2009 |
20110233027 | Tablet Flow - Tablet flow for the conveying away of tablets pressed in a tablet press, with a main flow channel, which has at least one branching into at least one first flow channel and at least one second flow channel separated from the first flow channel by at least one separating wall, wherein a separator is provided at the branching, which can be actuated such that tablets are directed out of the main flow channel alternatively into the first flow channel or into the second flow channel, characterized in that the separator has a guide channel for the tablets and in that a guide gear drive is provided, with which the guide channel is moveable between a first position connecting the main flow channel with the first flow channel and a second position connecting the main flow channel with the second flow channel. | 09-29-2011 |
Patent application number | Description | Published |
20100332904 | Testing of Distributed Systems - In an embodiment, a method is provided for tracking a test. In this method, a test session identifier is transmitted to a test system. The test session identifier identifies a particular test session. A test of a component is triggered at the test system, and this test provides test results, which are received from the test system. The test results include the test session identifier, which allows the tests to be associated with the particular test session. | 12-30-2010 |
20110023009 | Computer Software Development Methods And Systems - A method is provided for providing one or more services by a service provider to a service consumer. The method may include defining a meta-model describing at least one core service and at least one compound service; creating a model for the core service based on the meta-model; and implementing the core service on the service provider based on the model. The method may also include implementing the compound service on the service provider and implementing a generic access interface on the service consumer to dynamically access the core service and the compound service. | 01-27-2011 |
20110138358 | SYSTEMS AND METHODS FOR ANALYZING TEST COVERAGE AT AN ORGANIZATIONAL LEVEL - Disclosed are methods and systems for calculating test coverage of a software organizational schema. The method and systems involve retrieving the software organizational schema associated with an application, receiving an assigned weight factor to the one or more software organizational schema components associated with the application, determining a number of processed code lines and a total number of the code lines associated with the one or more software organizational schema components, calculating a test coverage for the one or more software organizational schema components based on the weight factor, the number of processed code lines and the total number of code lines of the software organizational schema component. | 06-09-2011 |
20120159445 | ASPECT AND SYSTEM LANDSCAPE CAPABILITY-DRIVEN AUTOMATIC TESTING OF SOFTWARE APPLICATIONS - In a system and a method, a sub-test catalog is retrieved from a test catalog repository. A test aspect of the sub-test catalog is compared to an aspect of a software application to be tested. A required system capability of the sub-test catalog is compared to the capabilities of a system landscape based on a determination that the sub-test catalog test aspect matches the aspect of the software application to be tested. The system landscape includes at least one system. The sub-test catalog is added to a master test catalog based on a determination that the required system capability of the sub-test catalog matches the system landscape capabilities. | 06-21-2012 |
20120173929 | SYSTEM AND METHOD FOR TESTING A SOFTWARE UNIT OF AN APPLICATION - A system, computer readable storage medium including instructions, and a computer-implemented method for testing a software unit of an application is described. A method signature for a method of the software unit of the application is received. A generic test specification for a generic test of the method is identified based on the method signature, the generic test specification being one of a plurality of test specifications, wherein the generic test specification includes a definition for at least one reference input parameter value of the method and a definition for at least one reference output parameter value of the method. The method is executed using the at least one reference input parameter value to produce at least one test output parameter value. A test result is determined based on a comparison between the at least one test output parameter value and the at least one reference output parameter value. | 07-05-2012 |
20130262513 | GENERIC APPLICATION PERSISTENCE DATABASE - A method includes receiving a request from a client to perform an application operation, transmitting a generic application persistency statement defined in an application template corresponding to the application, where the template belongs to a set of predefined application templates. Searching a logical database for a first location having entries corresponding to a technical key and an operation identifier, determining a second technical key based on content stored at the first location, searching the logical database for a second location having entries corresponding to the second technical key and a dataset key, determining a third technical key based on content stored at the second location, and accessing locations of the logical database based on the third technical key, wherein the contents of the logical database locations correspond to content of a physical database. A system to implement the method and a computer readable medium are disclosed. | 10-03-2013 |
20140280367 | SILO-AWARE DATABASES - A system receives a request from an application to access a database. The system forms a database table proxy for a logical database. One or more database silos are assigned to the database table proxy. A default database silo from the one or more database silos is defined for the database table proxy. A database silo of the database table proxy corresponding to an application requesting access to the logical database is accessed with a database engine. | 09-18-2014 |
Patent application number | Description | Published |
20110045188 | METHOD FOR COATING METAL SURFACES WITH A WAX-CONTAINING LUBRICANT COMPOSITION - The invention relates to a method for preparing metal workpieces for cold forming by applying a lubricant layer either to a metal surface or to a metal surface which has been pre-coated with e.g., a conversion coating. The lubricant layer is formed by contacting the surface with an aqueous lubricant composition which has a content in at least two waxes having distinct properties and a content in organic polymer material, the organic polymer material used predominantly being monomers, oligomers, co-oligomers, polymers and copolymers based on ionomer, acrylic acid/methacrylic acid, epoxide, ethylene, propylene, styrene, urethane, the ester or salt thereof. The invention to the corresponding lubricant composition, to the lubricant layer produced thereof and to its use. | 02-24-2011 |
20110048090 | METHOD FOR COATING METAL SURFACES WITH A LUBRICANT COMPOSITION - The invention relates to a method for preparing metal workpieces for cold forming by applying a lubricant layer either to a metal surface or to a metal surface which has been pre-coated with e.g., a conversion coating. The lubricant layer is formed by contacting the surface with an aqueous lubricant composition which has a content in at least one water soluble, water-containing or water-binding oxide or silicate and a content in organic polymer material, the organic polymer material used predominantly being monomers, oligomers, co-oligomers, polymers and copolymers based on ionomer, acrylic acid/methacrylic acid, epoxide, ethylene, propylene, styrene, urethane, the ester or salt thereof. The invention to the corresponding lubricant composition, to the lubricant layer produced thereof and to its use. | 03-03-2011 |
20110100081 | METHOD FOR COATING METAL SURFACES WITH A PHOSPHATE LAYER AND THEN WITH A POLYMER LUBRICANT LAYER - The invention relates to a method for preparing metal workpieces for cold forming by first applying a phosphate layer and then applying a lubricant layer which has a major content in organic polymer material. The phosphate layer is formed by an aqueous acidic phosphating solution having a major content in calcium, magnesium or manganese and phosphate. The lubricant layer is formed by contacting the phosphated surface with an aqueous lubricant composition which has a content in organic polymer material based on ionomer and optionally also non-ionomer the organic polymer material used predominantly being monomers, oligomers, co-oligomers, polymers or copolymers based on ionomer, acrylic acid/methacrylic acid, epoxide, ethylene, polyamide, propylene, styrene, urethane, the ester or salt thereof. The invention also relates to the corresponding lubricant composition, to the lubricant layer produced thereof and to its use. | 05-05-2011 |